Brief: I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

NovaBridge Biosciences

07/03/2025 12:02

March 7 (Reuters) - I-Mab IMAB.O:

I-MAB ANNOUNCES ACCELERATED GIVASTOMIG PHASE 1B STUDY PROGRESS

I-MAB: PHASE 1B DOSE ESCALATION DATA EXPECTED TO BE PRESENTED IN 2H 2025

I-MAB: TOPLINE RESULTS FROM 40-PATIENT DOSE EXPANSION STUDY EXPECTED IN 1H 2026

Source text: ID:nGNX10fQFG

Further company coverage: IMAB.O

 ((Reuters.Briefs@thomsonreuters.com;))